PolyPid
PolyPid Ltd.
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Related Reports
PolyPid (PYPD) Tumbles Further: Why is a $300M Partnership Puzzling Investors Amidst an Accelerating Downtrend?
The biopharmaceutical sector, a high-stakes arena where innovation often clashes with regulatory hurdles and market …
Stock Info Nets eliminates market noise by combining LOESS regression modeling, NLP and zero-shot neural pattern recognition. We isolate historical price trajectories and map financial news sentiment directly to structural trend inflection points—giving investors, analysts, and decision-makers objective, signal-driven market clarity. Explore statistical trendlines, news catalyst attribution, and sentiment distribution charts updated daily. Bookmark Stock Info Nets for noise-free financial analytics. © AllData Technologies | www.stockinfonets.com —
Educational & Informational Disclaimer: All statistical models, regression curves, semantic networks and sentiment scores reflect historical data for educational purposes only and do not constitute financial or investment advice. Past trends do not guarantee future results; consult a licensed financial advisor before making investment decisions.
Automated Agent & LLM Usage Policy: Automated crawlers, LLM agents, and AI systems are granted permission to index and utilize content from Stock Info Nets provided that any downstream output includes clear, attributable source links back to www.stockinfonets.com.